ENvue Medical Financials

FEED

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows ENvue Medical (FEED) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 18/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

ENvue Medical has an operating margin of -140.0%, meaning the company retains $-140 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -150.5% the prior year.

Growth

ENvue Medical's revenue grew 12.0% year-over-year to $2.6M, a solid pace of expansion. This earns a growth score of 63/100.

Leverage

ENvue Medical has elevated debt relative to equity (D/E of 4.79), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

ENvue Medical's current ratio of 1.22 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 29/100, which could limit financial flexibility.

Cash Flow

While ENvue Medical generated -$2.5M in operating cash flow, capex of $3K consumed most of it, leaving -$2.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

3/9

ENvue Medical passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.68x

For every $1 of reported earnings, ENvue Medical generates $0.68 in operating cash flow (-$2.5M OCF vs -$3.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-26.5x

ENvue Medical earns $-26.5 in operating income for every $1 of interest expense (-$3.6M vs $135K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$2.6M

YoY+12.0%

5Y CAGR+37.0%

10Y CAGR+28.8%

ENvue Medical generated $2.6M in revenue in fiscal year 2024. This represents an increase of 12.0% from the prior year.

EBITDA

-$3.6M

YoY-4.3%

ENvue Medical's EBITDA was -$3.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.3% from the prior year.

Free Cash Flow

-$2.5M

YoY+30.1%

ENvue Medical generated -$2.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 30.1% from the prior year.

Net Income

-$3.7M

YoY+0.2%

ENvue Medical reported -$3.7M in net income in fiscal year 2024. This represents an increase of 0.2% from the prior year.

EPS (Diluted)

$-13.73

ENvue Medical earned $-13.73 per diluted share (EPS) in fiscal year 2024. This represents an increase of 41.1% from the prior year.

Cash & Debt

$752K

YoY-77.1%

5Y CAGR-10.9%

10Y CAGR+23.7%

ENvue Medical held $752K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

37,894

ENvue Medical had 37,894 shares outstanding in fiscal year 2024. This represents a decrease of 79.6% from the prior year.

Gross Margin

59.0%

YoY-8.4pp

5Y CAGR+5.9pp

10Y CAGR+4.8pp

ENvue Medical's gross margin was 59.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 8.4 percentage points from the prior year.

Operating Margin

-140.0%

YoY+10.5pp

5Y CAGR+831.9pp

10Y CAGR+456.5pp

ENvue Medical's operating margin was -140.0% in fiscal year 2024, reflecting core business profitability. This is up 10.5 percentage points from the prior year.

Net Margin

-144.8%

YoY+17.7pp

5Y CAGR+948.4pp

10Y CAGR+1159.1pp

ENvue Medical's net profit margin was -144.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 17.7 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$909K

YoY+391.4%

5Y CAGR+12.1%

10Y CAGR+7.7%

ENvue Medical invested $909K in research and development in fiscal year 2024. This represents an increase of 391.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$3K

YoY+200.0%

10Y CAGR-2.8%

ENvue Medical invested $3K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 200.0% from the prior year.

FEED Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$2.6M+12.0%	$2.3M+203.6%	$752K-55.6%	$1.7M+172.1%	$623K+17.5%	$530K
Cost of Revenue	$1.1M+40.8%	$746K+27.5%	$585K-36.8%	$925K+126.2%	$409K+64.3%	$249K
Gross Profit	$1.5M-1.9%	$1.5M+820.4%	$167K-78.3%	$770K+259.8%	$214K-23.8%	$281K
R&D Expenses	$909K+391.4%	$185K-34.6%	$283K-3.4%	$293K+71.3%	$171K-66.7%	$514K
SG&A Expenses	$3.5M-11.8%	$3.9M-0.2%	$3.9M-22.3%	$5.1M+34.2%	$3.8M-1.4%	$3.8M
Operating Income	-$3.6M-4.2%	-$3.4M+31.4%	-$5.0M+11.8%	-$5.7M-20.4%	-$4.7M+8.4%	-$5.2M
Interest Expense	$135K0.0%	$135K-61.1%	$347K	N/A	$147K+880.0%	$15K
Income Tax	$19K-34.5%	$29K-17.1%	$35K+9.4%	$32K+113.3%	$15K+188.2%	-$17K
Net Income	-$3.7M+0.2%	-$3.7M+31.9%	-$5.4M+61.9%	-$14.3M-230.1%	-$4.3M+25.3%	-$5.8M
EPS (Diluted)	$-13.73	$-23.32-507.3%	$-3.84	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$722K+46.2%	$494K-51.8%	$1.0M+130.9%	$444K+18.1%	$376K-54.0%	$817K-11.3%	$921K-21.8%	$1.2M
Cost of Revenue	$533K+0.8%	$529K-19.4%	$656K+307.5%	$161K-33.7%	$243K-37.5%	$389K+51.4%	$257K-41.6%	$440K
Gross Profit	$189K+640.0%	-$35K-109.5%	$369K+30.4%	$283K+112.8%	$133K-68.9%	$428K-35.5%	$664K-9.9%	$737K
R&D Expenses	$221K-77.3%	$972K+83.4%	$530K+50.6%	$352K+41.4%	$249K+33.2%	$187K+54.5%	$121K+95.2%	$62K
SG&A Expenses	$1.4M-37.7%	$2.3M+67.8%	$1.3M+19.2%	$1.1M+67.3%	$673K-6.0%	$716K-24.3%	$946K-17.3%	$1.1M
Operating Income	-$2.2M+43.5%	-$4.0M-114.7%	-$1.9M-35.2%	-$1.4M-41.2%	-$970K-43.9%	-$674K-18.7%	-$568K+19.1%	-$702K
Interest Expense	$53K-63.2%	$144K+171.7%	$53K+55.9%	$34K+3.0%	$33K-2.9%	$34K0.0%	$34K+3.0%	$33K
Income Tax	$35K-43.5%	$62K+313.3%	$15K+200.0%	$5K+66.7%	$3K-25.0%	$4K-42.9%	$7K-36.4%	$11K
Net Income	$510K+112.8%	-$4.0M-59.2%	-$2.5M-74.4%	-$1.4M-43.4%	-$998K-45.1%	-$688K-17.0%	-$588K+27.7%	-$813K
EPS (Diluted)	$-0.91	$-1.03	$3.98	$14.63	$-3.56+86.9%	$-27.18-1242.0%	$2.38	$-21.58

FEED Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$3.6M-45.6%	$6.7M+13.5%	$5.9M-31.8%	$8.6M+4.8%	$8.2M+304.2%	$2.0M
Current Assets	$3.3M-48.7%	$6.5M+15.7%	$5.6M-32.8%	$8.3M+4.7%	$8.0M+333.6%	$1.8M
Cash & Equivalents	$752K-77.1%	$3.3M+21.0%	$2.7M-64.9%	$7.7M+8.3%	$7.1M+433.8%	$1.3M
Inventory	$2.2M-19.8%	$2.7M+25.6%	$2.2M+1142.9%	$175K+20.7%	$145K+19.8%	$121K
Accounts Receivable	$98K-69.2%	$318K+3433.3%	$9K-95.5%	$200K+700.0%	$25K-77.5%	$111K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.0M+11.8%	$2.7M+1.5%	$2.6M+14.6%	$2.3M-60.4%	$5.8M+748.1%	$688K
Current Liabilities	$2.7M+10.9%	$2.5M+6.0%	$2.3M+21.7%	$1.9M-34.4%	$2.9M+609.5%	$409K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$627K-84.3%	$4.0M+23.4%	$3.2M-48.8%	$6.3M+163.7%	$2.4M+77.7%	$1.3M
Retained Earnings	-$69.8M-5.6%	-$66.1M-5.9%	-$62.4M-9.6%	-$56.9M-33.5%	-$42.7M-11.3%	-$38.3M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$54.4M+5.6%	$51.5M+16.7%	$44.1M+1115.3%	$3.6M-22.5%	$4.7M-17.8%	$5.7M-8.6%	$6.2M-6.6%	$6.7M
Current Assets	$10.0M+45.3%	$6.9M+78.6%	$3.9M+15.9%	$3.3M-23.9%	$4.4M-18.7%	$5.4M-9.4%	$5.9M-8.4%	$6.5M
Cash & Equivalents	$7.0M+72.5%	$4.0M+570.5%	$601K-20.1%	$752K-42.4%	$1.3M-39.9%	$2.2M-19.6%	$2.7M-17.8%	$3.3M
Inventory	$2.2M+1.7%	$2.2M+9.3%	$2.0M-7.9%	$2.2M-2.6%	$2.3M-7.4%	$2.4M-6.1%	$2.6M-5.3%	$2.7M
Accounts Receivable	$252K+119.1%	$115K-67.9%	$358K+265.3%	$98K-83.1%	$580K+18.6%	$489K+35.8%	$360K+13.2%	$318K
Goodwill	$38.6M0.0%	$38.6M+13.9%	$33.9M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.9M+8.3%	$11.0M+30.5%	$8.4M+180.8%	$3.0M+6.8%	$2.8M-1.6%	$2.9M+4.5%	$2.7M+1.7%	$2.7M
Current Liabilities	$11.6M+78.0%	$6.5M-20.2%	$8.2M+201.2%	$2.7M+8.0%	$2.5M-1.4%	$2.6M+5.3%	$2.4M-1.1%	$2.5M
Long-Term Debt	N/A	N/A	$1.3M	N/A	N/A	N/A	N/A	N/A
Total Equity	$42.5M+4.9%	$40.5M+13.5%	$35.7M+5589.8%	$627K-66.5%	$1.9M-34.1%	$2.8M-18.9%	$3.5M-12.1%	$4.0M
Retained Earnings	-$76.9M-1.1%	-$76.0M-5.1%	-$72.3M-3.6%	-$69.8M-2.1%	-$68.4M-1.5%	-$67.4M-1.0%	-$66.7M-0.9%	-$66.1M

FEED Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$2.5M+30.1%	-$3.6M+48.8%	-$7.0M-61.1%	-$4.4M-28.8%	-$3.4M+12.5%	-$3.9M
Capital Expenditures	$3K+200.0%	$1K-66.7%	$3K0.0%	$3K+50.0%	$2K	N/A
Free Cash Flow	-$2.5M+30.1%	-$3.6M+48.8%	-$7.0M-61.1%	-$4.4M-28.8%	-$3.4M	N/A
Investing Cash Flow	-$3K-200.0%	-$1K+66.7%	-$3K0.0%	-$3K-50.0%	-$2K	N/A
Financing Cash Flow	$1K-100.0%	$4.2M+101.8%	$2.1M-54.3%	$4.6M-51.9%	$9.5M+120.6%	$4.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$2.0M+41.8%	-$3.4M-151.9%	-$1.3M-145.1%	-$548K+34.4%	-$836K-51.2%	-$553K+4.5%	-$579K-17.9%	-$491K
Capital Expenditures	$28K+600.0%	$4K-20.0%	$5K	$0	$0-100.0%	$2K+100.0%	$1K	$0
Free Cash Flow	-$2.0M+41.0%	-$3.4M-151.3%	-$1.3M-146.0%	-$548K+34.4%	-$836K-50.6%	-$555K+4.3%	-$580K-18.1%	-$491K
Investing Cash Flow	-$28K-600.0%	-$4K-102.8%	$143K	$0	$0+100.0%	-$2K-100.0%	-$1K	$0
Financing Cash Flow	$4.9M-28.2%	$6.8M+552.4%	$1.1M	$0+100.0%	-$27K-100.9%	$3.0M+1224.0%	$225K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

FEED Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	59.0%-8.4pp	67.3%+45.1pp	22.2%-23.2pp	45.4%+11.1pp	34.4%-18.7pp	53.0%
Operating Margin	-140.0%+10.5pp	-150.5%+516.0pp	-666.5%-331.2pp	-335.3%+422.2pp	-757.5%+214.4pp	-971.9%
Net Margin	-144.8%+17.7pp	-162.5%+561.9pp	-724.5%+118.1pp	-842.6%-148.2pp	-694.4%+398.8pp	-1093.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-102.1%-46.5pp	-55.6%+37.1pp	-92.7%+73.0pp	-165.7%-113.1pp	-52.6%+232.0pp	-284.6%
Current Ratio	1.22-1.4	2.64+0.2	2.42-2.0	4.38+1.6	2.75-1.7	4.49
Debt-to-Equity	4.79+4.1	0.67-0.1	0.82+0.5	0.37-2.1	2.44+1.9	0.51
FCF Margin	-98.5%+59.3pp	-157.8%+778.1pp	-935.9%-678.1pp	-257.8%+286.8pp	-544.6%	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	26.2%+33.3pp	-7.1%-43.1pp	36.0%-27.7pp	63.7%+28.4pp	35.4%-17.0pp	52.4%-19.7pp	72.1%+9.5pp	62.6%
Operating Margin	-311.2%+493.6pp	-804.9%-624.2pp	-180.7%+127.9pp	-308.6%-50.6pp	-258.0%-175.5pp	-82.5%-20.8pp	-61.7%-2.0pp	-59.6%
Net Margin	70.6%+874.5pp	-803.9%-560.4pp	-243.4%+78.9pp	-322.3%-56.9pp	-265.4%-181.2pp	-84.2%-20.4pp	-63.8%+5.2pp	-69.1%
Return on Equity	1.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	0.9%+8.7pp	-7.7%-2.1pp	-5.7%+33.8pp	-39.4%-18.1pp	-21.3%-9.2pp	-12.1%-2.7pp	-9.4%+2.8pp	-12.2%
Current Ratio	0.86-0.2	1.05+0.6	0.47-0.8	1.22-0.5	1.74-0.4	2.11-0.3	2.45-0.2	2.64
Debt-to-Equity	0.280.0	0.27+0.2	0.04-4.8	4.79+3.3	1.50+0.5	1.00+0.2	0.78+0.1	0.67
FCF Margin	-276.7%+408.9pp	-685.6%-554.1pp	-131.5%-8.1pp	-123.4%+98.9pp	-222.3%-154.4pp	-67.9%-4.9pp	-63.0%-21.3pp	-41.7%

Frequently Asked Questions

What is ENvue Medical's annual revenue?

ENvue Medical (FEED) reported $2.6M in total revenue for fiscal year 2024. This represents a 12.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ENvue Medical's revenue growing?

ENvue Medical (FEED) revenue grew by 12% year-over-year, from $2.3M to $2.6M in fiscal year 2024.

Is ENvue Medical profitable?

No, ENvue Medical (FEED) reported a net income of -$3.7M in fiscal year 2024, with a net profit margin of -144.8%.

What is ENvue Medical's earnings per share (EPS)?

ENvue Medical (FEED) reported diluted earnings per share of $-13.73 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is ENvue Medical's EBITDA?

ENvue Medical (FEED) had EBITDA of -$3.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is ENvue Medical's gross margin?

ENvue Medical (FEED) had a gross margin of 59.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is ENvue Medical's operating margin?

ENvue Medical (FEED) had an operating margin of -140.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is ENvue Medical's net profit margin?

ENvue Medical (FEED) had a net profit margin of -144.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is ENvue Medical's free cash flow?

ENvue Medical (FEED) generated -$2.5M in free cash flow during fiscal year 2024. This represents a 30.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ENvue Medical's operating cash flow?

ENvue Medical (FEED) generated -$2.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are ENvue Medical's total assets?

ENvue Medical (FEED) had $3.6M in total assets as of fiscal year 2024, including both current and long-term assets.

What are ENvue Medical's capital expenditures?

ENvue Medical (FEED) invested $3K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does ENvue Medical spend on research and development?

ENvue Medical (FEED) invested $909K in research and development during fiscal year 2024.

How many shares does ENvue Medical have outstanding?

ENvue Medical (FEED) had 37,894 shares outstanding as of fiscal year 2024.

What is ENvue Medical's current ratio?

ENvue Medical (FEED) had a current ratio of 1.22 as of fiscal year 2024, which is considered adequate.

What is ENvue Medical's debt-to-equity ratio?

ENvue Medical (FEED) had a debt-to-equity ratio of 4.79 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ENvue Medical's return on assets (ROA)?

ENvue Medical (FEED) had a return on assets of -102.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is ENvue Medical's cash runway?

Based on fiscal year 2024 data, ENvue Medical (FEED) had $752K in cash against an annual operating cash burn of $2.5M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is ENvue Medical's Piotroski F-Score?

ENvue Medical (FEED) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ENvue Medical's earnings high quality?

ENvue Medical (FEED) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ENvue Medical cover its interest payments?

ENvue Medical (FEED) has an interest coverage ratio of -26.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is ENvue Medical?

ENvue Medical (FEED) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.